DK1572745T3 - Antistof anti-humant NogoA og dets farmaceutiske anvendelse - Google Patents

Antistof anti-humant NogoA og dets farmaceutiske anvendelse

Info

Publication number
DK1572745T3
DK1572745T3 DK03782350.7T DK03782350T DK1572745T3 DK 1572745 T3 DK1572745 T3 DK 1572745T3 DK 03782350 T DK03782350 T DK 03782350T DK 1572745 T3 DK1572745 T3 DK 1572745T3
Authority
DK
Denmark
Prior art keywords
human
pharmaceutical use
binding molecule
human nogoa
antibody anti
Prior art date
Application number
DK03782350.7T
Other languages
English (en)
Inventor
Carmen Barske
Anis Khusro Mir
Thomas Oertle
Lisa Schnell
Martin E Schwab
Alessandra Vitaliti
Mauro Zurini
Original Assignee
Novartis Ag
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Univ Zuerich filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1572745T3 publication Critical patent/DK1572745T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK03782350.7T 2002-12-10 2003-12-09 Antistof anti-humant NogoA og dets farmaceutiske anvendelse DK1572745T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0228832.2A GB0228832D0 (en) 2002-12-10 2002-12-10 Organic compound
PCT/EP2003/013960 WO2004052932A2 (en) 2002-12-10 2003-12-09 Antibody (“11c7”) anti nogo a and its pharmaceutical use

Publications (1)

Publication Number Publication Date
DK1572745T3 true DK1572745T3 (da) 2010-10-25

Family

ID=9949456

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03782350.7T DK1572745T3 (da) 2002-12-10 2003-12-09 Antistof anti-humant NogoA og dets farmaceutiske anvendelse

Country Status (25)

Country Link
US (2) US7785593B2 (da)
EP (1) EP1572745B1 (da)
JP (1) JP4504200B2 (da)
KR (1) KR101215801B1 (da)
CN (1) CN100384877C (da)
AT (1) ATE475671T1 (da)
AU (1) AU2003289998B2 (da)
BR (1) BR0317161A (da)
CA (1) CA2509068C (da)
CY (1) CY1110848T1 (da)
DE (1) DE60333585D1 (da)
DK (1) DK1572745T3 (da)
EC (1) ECSP055849A (da)
ES (1) ES2349293T3 (da)
GB (1) GB0228832D0 (da)
HK (1) HK1084676A1 (da)
IL (1) IL169018A (da)
MX (1) MXPA05006265A (da)
NO (1) NO20053304L (da)
PL (1) PL210720B1 (da)
PT (1) PT1572745E (da)
RU (1) RU2350623C2 (da)
SI (1) SI1572745T1 (da)
WO (1) WO2004052932A2 (da)
ZA (1) ZA200504522B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
MY144612A (en) * 2003-12-22 2011-10-14 Glaxo Group Ltd Nogo-a neutralising immunoglobulins for treatment of neurological diseases
KR20080030960A (ko) * 2005-07-05 2008-04-07 글락소 그룹 리미티드 Ｎｏｇｏ―ａ에 특이적인 인간화된 항체 및 이의 약제학적용도
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
WO2009056509A1 (en) * 2007-11-02 2009-05-07 Novartis Ag Improved nogo-a binding molecules and pharmaceutical use thereof
JP2011527317A (ja) * 2008-07-11 2011-10-27 グラクソ グループ リミテッド Ｎｏｇｏ−ａアンタゴニストによる筋萎縮性側索硬化症の治療
WO2012004773A1 (en) 2010-07-09 2012-01-12 Universite De Geneve New uses of nogo-a inhibitors and related methods
CA2876284A1 (en) 2012-07-05 2014-01-09 Glaxo Group Limited Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
JP6604942B2 (ja) * 2013-06-13 2019-11-13 バイオマトリカ，インク． 細胞安定化
CA3015619A1 (en) 2016-03-01 2017-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)
EP4048692A2 (en) 2019-10-24 2022-08-31 NovaGo Therapeutics AG Novel anti-nogo-a antibodies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308573D0 (en) 1983-03-29 1983-05-05 British Nuclear Fuels Ltd Filament impregnating/coating
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5180820A (en) 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
DK0531472T3 (da) 1991-03-06 2003-12-01 Merck Patent Gmbh Humaniserede monoklonale antistoffer
EP1098972B1 (en) 1998-07-22 2010-09-29 SmithKline Beecham Limited Protein similar to neuroendocrine-specific protein, and encoding cdna
EP1124846B1 (en) 1998-11-06 2009-07-01 University of Zürich Nucleotide and protein sequences of nogo genes and methods based thereon
CU22921A1 (es) 1999-11-16 2004-02-20 Centro Inmunologia Molecular Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales
AU784349C (en) 2000-01-12 2006-09-28 Yale University Nogo receptor-mediated blockade of axonal growth
EP1385545B1 (en) * 2001-04-30 2009-01-07 Eli Lilly And Company Humanized antibodies recognizing the beta-amyloid peptide
DE20110806U1 (de) 2001-06-29 2001-12-20 Jack Wolfskin Ausrüstung für Draussen GmbH, 65510 Idstein Zelt
EP2990394A1 (en) * 2001-11-30 2016-03-02 Biogen MA Inc. Antibodies against monocyte chemotactic proteins
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
MY144612A (en) 2003-12-22 2011-10-14 Glaxo Group Ltd Nogo-a neutralising immunoglobulins for treatment of neurological diseases
US7596225B2 (en) * 2005-06-30 2009-09-29 Alcatl-Lucent Usa Inc. Method for refreshing a pairwise master key

Also Published As

Publication number Publication date
IL169018A (en) 2012-07-31
EP1572745B1 (en) 2010-07-28
NO20053304D0 (no) 2005-07-06
US20060183678A1 (en) 2006-08-17
CA2509068C (en) 2012-02-07
JP2006523087A (ja) 2006-10-12
EP1572745A2 (en) 2005-09-14
CY1110848T1 (el) 2015-06-10
PL377506A1 (pl) 2006-02-06
PT1572745E (pt) 2010-10-21
AU2003289998A1 (en) 2004-06-30
PL210720B1 (pl) 2012-02-29
US20110059110A1 (en) 2011-03-10
RU2350623C2 (ru) 2009-03-27
WO2004052932A3 (en) 2004-10-21
CN1747971A (zh) 2006-03-15
ATE475671T1 (de) 2010-08-15
KR20050095768A (ko) 2005-09-30
AU2003289998B2 (en) 2008-02-14
KR101215801B1 (ko) 2012-12-26
SI1572745T1 (sl) 2010-12-31
ES2349293T3 (es) 2010-12-29
GB0228832D0 (en) 2003-01-15
RU2005121669A (ru) 2007-01-20
ECSP055849A (es) 2005-09-20
DE60333585D1 (de) 2010-09-09
CA2509068A1 (en) 2004-06-24
HK1084676A1 (en) 2006-08-04
US7785593B2 (en) 2010-08-31
JP4504200B2 (ja) 2010-07-14
NO20053304L (no) 2005-09-07
US8535666B2 (en) 2013-09-17
ZA200504522B (en) 2006-03-29
BR0317161A (pt) 2005-11-01
WO2004052932A2 (en) 2004-06-24
MXPA05006265A (es) 2005-12-05
CN100384877C (zh) 2008-04-30

Similar Documents

Publication Publication Date Title
HK1084676A1 (en) Antibody anti human nogo a and its pharmaceutical use
CY1120252T1 (el) Μορια δεσμευσης αντιγονου με αυξημενη συγγενεια προσδεσης στον υποδοχεα fc και λειτουργια τελεστη
ECSP056263A (es) Anticuerpos humanizados que reconocen el péptido beta amiloideo
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
ATE373719T1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
EA200700136A1 (ru) Анти-cd154-антитела
WO2006083964A3 (en) Modified fusion molecules for treatment of allergic disease
WO2003034903A3 (en) Psma antibodies and protein multimers
TW200500377A (en) Method of humanizing immune system molecules
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
ATE455127T1 (de) Humane anti-humane cd3-bindungsmoleküle
ATE382053T1 (de) System zur antikörperexpression und- synthese
BRPI0715660B8 (pt) anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal
EA200901436A1 (ru) Антигенсвязывающие белки, связывающие par-2
ATE459004T1 (de) Ligand für den formylpeptidrezeptorähnlichen- 2 (fprl2) g protein gekoppelten rezeptor und dessen anwendung
TW200635946A (en) Binding proteins specific for human matriptase
WO2007039256A3 (de) Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
TNSN06085A1 (en) Nogo-a binding with enhanced affinity and pharmaceutical use thereof
ATE370235T1 (de) Rekombinantpeptide hergeleitet vom mc3 antikörper gegen ba46, verfahren zu deren verwendung und verfahren zur humanisierung von antikörperpeptiden
EP1411962A4 (en) MONOCLONAL ANTIBODY TREATMENT OF PANCREATIC CANCER
BRPI0407031A (pt) Composições e métodos para tratamento de câncer empregando igsf9 e liv-1
PE20090981A1 (es) Moleculas aglutinantes de nogo-a mejoradas y uso farmaceutico de las mismas
ATE312921T1 (de) Antigene polypeptide aus neisseria meningitidis, dafür kodierende polynukleotide und entsprechende schützende antikörper
WO2004032832A3 (en) Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment